Host genetic factors in hepatitis B infection, liver cancer and vaccination response: A review with a focus on Africa

Science of the Total Environment

Volumn 423, Issue , 2012, Pages 202-209

  Hennig, Branwen J ^a   Hall, Andrew J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

HBV; HCC; Host genetic variability; Persistence; Vaccine induced immunity

Indexed keywords

GENETIC VARIABILITY; HBV; HCC; PERSISTENCE; VACCINE-INDUCED IMMUNITY;

GENES; VACCINES; VIRUSES;

DISEASES;

HEPATITIS B VACCINE;

CANCER; EPIDEMIOLOGY; GENETIC VARIATION; HEPATITIS; IMMUNITY; IMMUNIZATION; INFECTIOUS DISEASE; MORTALITY; PUBLIC HEALTH; VACCINATION; VACCINE;

AFRICA; ARTICLE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEPATITIS B; HEREDITY; HERITABILITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENETICS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION;

AFRICA; GENETIC VARIATION; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNITY, ACTIVE; LIVER NEOPLASMS; MALE; PREVALENCE;

AFRICA;

HEPATITIS B VIRUS;

EID: 84859007686     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2010.09.036     Document Type: Article

References (80)

1. Ahn S.H., Han K.H., Park J.Y., Lee C.K., Kang S.W., Chon C.Y., et al. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology 2000, 31:1371-1373.
2. Bah E., Parkin D.M., Hall A.J., Jack A.D., Whittle H. Cancer in the Gambia: 1988-97. Br J Cancer 2001, 84:1207-1214.
3. Beasley R.P., Hwang L.Y., Stevens C.E., Lin C.C., Hsieh F.J., Wang K.Y., et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983, 3:135-141.
4. Bellamy R., Ruwende C., McAdam K.P., Thursz M., Sumiya M., Summerfield J., et al. Mannose binding protein deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans. QJM 1998, 91:13-18.
5. Bellamy R., Ruwende C., Corrah T., McAdam K.P., Thursz M., Whittle H.C., et al. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis 1999, 179:721-724.
6. Blumberg B.S., Friedlaender J.S., Woodside A., Sutnick A.I., London W.T. Hepatitis and Australia antigen: autosomal recessive inheritance of susceptibility to infection in humans. Proc Natl Acad Sci USA 1969, 62:1108-1115.
7. Bosch J., Brugera M., Rodes J. Familial spread of type-B hepatitis. Lancet 1973, 2:457.
8. Bronowicki J.P., Abdelmouttaleb I., Peyrin-Biroulet L., Venard V., Khiri H., Chabi N., et al. Methylenetetrahydrofolate reductase 677T allele protects against persistent HBV infection in West Africa. J Hepatol 2008, 48:532-539.
9. Chen C.C., Yang S.Y., Liu C.J., Lin C.L., Liaw Y.F., Lin S.M., et al. Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol 2005, 34:1310-1318.
10. Dash B., Afriyie-Gyawu E., Huebner H.J., Porter W., Wang J.S., Jolly P.E., et al. Determinants of the variability of aflatoxin-albumin adduct levels in Ghanaians. J Toxicol Environ Health A 2007, 70:58-66.
11. Davila S., Froeling F.E., Tan A., Bonnard C., Boland G.J., Snippe H., et al. New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun 2010, 11:232-238.
12. de Andrade D.R., de Andrade D.R. The influence of the human genome on chronic viral hepatitis outcome. Rev Inst Med Trop São Paulo 2004, 46:119-126.
13. De Silvestri A., Pasi A., Martinetti M., Belloni C., Tinelli C., Rondini G., et al. Family study of non-responsiveness to hepatitis B vaccine confirms the importance of HLA class III C4A locus. Genes Immun 2001, 2:367-372.
14. Decker R.H. Diagnosis of acute and chronic hepatitis B. Viral Hepatitis. Churchill Livingstone 1998, 201-216. A.J. Zuckerman, D.L. Thomas (Eds.).
15. Demir G., Belentepe S., Ozguroglu M., Celik A.F., Sayhan N., Tekin S., et al. Simultaneous presentation of hepatocellular carcinoma in identical twin brothers. Med Oncol 2002, 19:113-116.
16. Dickinson J.A., Wun Y.T., Wong S.L. Modelling death rates for carriers of hepatitis B. Epidemiol Infect 2002, 128:83-92.
17. Dieye A., Obami-Itou V., Barry M.F., Raphenon G., Thiam A., Ndiaye R., et al. Association between Class I HLA alleles and HBs antigen carrier status among blood donors in Senegal. Dakar Méd 1999, 44:166-170.
18. Ezzikouri S., El Feydi A.E., Chafik A., Afifi R., El Kihal L., Benazzouz M., et al. Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCV-infected Moroccan patients. Mutat Res 2008, 649:1-6.
19. Frodsham A.J. Host genetics and the outcome of hepatitis B viral infection. Transpl Immunol 2005, 14:183-186.
20. Frodsham A.J., Zhang L., Dumpis U., Taib N.A., Best S., Durham A., et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci USA 2006, 103:9148-9153.
21. Furberg A.H., Ambrosone C.B. Molecular epidemiology, biomarkers and cancer prevention. Trends Mol Med 2001, 7:517-521.
22. GAVI Hepatitis B factsheet 2005.
23. Grob P., Jilg W., Bornhak H., Gerken G., Gerlich W., Gunther S., et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 2000, 62:450-455.
24. Hall A. Hepatitis Viruses. Principles of Medicine in Africa 2004, 709-719. Cambridge University Press, Cambridge. E. Parry, R. Godfrey, D. Mabey, G. Gill (Eds.).
25. Hall A.J., Yee L.J., Thomas S.L. Life course epidemiology and infectious diseases. Int J Epidemiol 2002, 31:300-301.
26. He Y.L., Zhao Y.R., Zhang S.L., Lin S.M. Host susceptibility to persistent hepatitis B virus infection. World J Gastroenterol 2006, 12:4788-4793.
27. Hennig B.J., Fielding K., Broxholme J., Diatta M., Mendy M., Moore C., et al. Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS ONE 2008, 3:e1898.
28. Hino O. Intentional delay of human hepatocarcinogenesis due to suppression of chronic hepatitis. Intervirology 2005, 48:6-9.
29. *1302 protect against chronic hepatitis B. J Hepatol 1997, 26:503-507.
30. Hohler T., Reuss E., Freitag C.M., Schneider P.M. A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A. Hepatology 2005, 42:72-76.
31. Jack A.D., Hall A.J., Maine N., Mendy M., Whittle H.C. What level of hepatitis B antibody is protective?. J Infect Dis 1999, 179:489-492.
32. Kamatani Y., Wattanapokayakit S., Ochi H., Kawaguchi T., Takahashi A., Hosono N., et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009, 41:591-595.
33. Kim Y.J., Lee H.S. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology 2005, 48:10-15.
34. Kimman T.G., Vandebriel R.J., Hoebee B. Genetic variation in the response to vaccination. Community Genet 2007, 10:201-217.
35. Kirk G.D., Turner P.C., Gong Y., Lesi O.A., Mendy M., Goedert J.J., et al. Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol Biomark Prev 2005, 14:373-379.
36. Kirk G.D., Bah E., Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis 2006, 27:2070-2082.
37. * - lessons from twins and peptide binding studies. Clin Exp Immunol 2005, 140:325-332.
38. Kruskall M.S., Alper C.A., Awdeh Z., Yunis E.J., Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J Exp Med 1992, 175:495-502.
39. Lin T.M., Chen C.J., Wu M.M., Yang C.S., Chen J.S., Lin C.C., et al. Hepatitis B virus markers in Chinese twins. Anticancer Res 1989, 9:737-741.
40. Lin J.B., Lin D.B., Chen S.C., Chen P.S., Chen W.K. Seroepidemiology of hepatitis A, B, C, and E viruses infection among preschool children in Taiwan. J Med Virol 2006, 78:18-23.
41. Lindemann M., Barsegian V., Siffert W., Ferencik S., Roggendorf M., Grosse-Wilde H. Role of G protein beta3 subunit C825T and HLA class II polymorphisms in the immune response after HBV vaccination. Virology 2002, 297:245-252.
42. Louagie H., Delanghe J., Desombere I., De Buyzere M., Hauser P., Leroux-Roels G. Haptoglobin polymorphism and the immune response after hepatitis B vaccination. Vaccine 1993, 11:1188-1190.
43. Milich D.R., Leroux-Roels G.G. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2003, 2:248-257.
44. Motta-Castro A.R., Martins R.M., Yoshida C.F., Teles S.A., Paniago A.M., Lima K.M., et al. Hepatitis B virus infection in isolated Afro-Brazilian communities. J Med Virol 2005, 77:188-193.
45. Newport M.J., Goetghebuer T., Weiss H.A., Whittle H., Siegrist C.A., Marchant A. Genetic regulation of immune responses to vaccines in early life. Genes Immun 2004, 5:122-129.
46. Newport M.J., Goetghebuer T., Marchant A. Hunting for immune response regulatory genes: vaccination studies in infant twins. Expert Rev Vaccin 2005, 4:739-746.
47. Obami-Itou V., Barry M.F., Raphenon G., Thiam A., Ndiaye R., Ndiaye M., et al. Serological HLA class I alleles in Senegalese blood donors detected HBs Ag positive. Immunol Lett 2000, 74:229-232.
48. Obayashi A., Okochi K., Mayumi M. Familial clustering of asymptomatic carriers of Australia antigen and patients with chronic liver disease or primary liver cancer. Gastroenterology 1972, 62:618-625.
49. Omer R.E., Verhoef L., Van't Veer P., Idris M.O., Kadaru A.M., Kampman E., et al. Peanut butter intake, GSTM1 genotype and hepatocellular carcinoma: a case-control study in Sudan. Cancer Causes Control 2001, 12:23-32.
50. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118:3030-3044.
51. Parkin D.M., Sitas F., Chirenje M., Stein L., Abratt R., Wabinga H. Part I: Cancer in Indigenous Africans-burden, distribution, and trends. Lancet Oncol 2008, 9:683-692.
52. Qin H., Liu B., Shi T., Liu Y., Sun Y., Ma Y. Tumour necrosis factor-alpha polymorphisms and hepatocellular carcinoma: a meta-analysis. J Int Med Res 2010, 38:760-768.
53. Ryckman K.K., Fielding K., Hill A.V., Mendy M., Rayco-Solon P., Sirugo G., et al. Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis. PLoS ONE 2010, 5.
54. Shih W.L., Yu M.W., Chen P.J., Yeh S.H., Lo M.T., Chang H.C., et al. Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. Oncogene 2006, 25:3219-3224.
55. Stroffolini T., Chiaramonte M., Craxi A., Franco E., Rapicetta M., Trivello R., et al. Baseline sero-epidemiology of hepatitis B virus infection in children and teenagers in Italy. A survey before mass hepatitis B vaccination. J Infect 1991, 22:191-199.
56. Sun W., Zhong F., Zhi L., Zhou G., He F. Systematic - omics analysis of HBV-associated liver diseases. Cancer Lett 2009, 286:89-95.
57. Sylla A., Diallo M.S., Castegnaro J., Wild C.P. Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach. Mutat Res 1999, 428:187-196.
58. Thio C.L., Carrington M., Marti D., O'Brien S.J., Vlahov D., Nelson K.E., et al. Class II HLA alleles and hepatitis B virus persistence in African Americans. J Infect Dis 1999, 179:1004-1006.
59. Thio C.L., Thomas D.L., Karacki P., Gao X., Marti D., Kaslow R.A., et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol 2003, 77:12083-12087.
60. Thio C.L., Mosbruger T.L., Kaslow R.A., Karp C.L., Strathdee S.A., Vlahov D., et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004, 78:11258-11262.
61. Thursz M. Genetic susceptibility in chronic viral hepatitis. Antivir Res 2001, 52:113-116.
62. Thursz M. MHC and the viral hepatitides. QJM 2001, 94:287-291.
63. Thursz M.R., Kwiatkowski D., Allsopp C.E., Greenwood B.M., Thomas H.C., Hill A.V. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995, 332:1065-1069.
64. Thursz M., Kwiatkowski D., McGuire W., Hill A.V., Thomas H.C. TNF promoter polymorphism and the outcome of hepatitis B virus infection. Gut 1996, 39:A19.
65. Tiemersma E.W., Omer R.E., Bunschoten A., van't Veer P., Kok F.J., Idris M.O., et al. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomark Prev 2001, 10:785-791.
66. Truelove A.L., Oleksyk T.K., Shrestha S., Thio C.L., Goedert J.J., Donfield S.M., et al. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. Int J Immunogenet 2008, 35:255-264.
67. Uwaifo A.O., Bababunmi E.A. Liver carcinogenesis in tropical Africa. IARC Sci Publ 1984, 59-88.
68. van der Sande M.A., Waight P., Mendy M., Rayco-Solon P., Hutt P., Fulford T., et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006, 193:1528-1535.
69. Van Loveren H., Van Amsterdam J.G., Vandebriel R.J., Kimman T.G., Rumke H.C., Steerenberg P.S., et al. Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors. Environ Health Perspect 2001, 109:757-764.
70. Viviani S., Carrieri P., Bah E., Hall A.J., Kirk G.D., Mendy M., et al. 20years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomark Prev 2008, 17:3216-3223.
71. Wang F.S. Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J Gastroenterol 2003, 9:641-644.
72. Wang C., Tang J., Song W., Lobashevsky E., Wilson C.M., Kaslow R.A. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004, 39:978-988.
73. WHO Hepatitis B fact sheet 2008.
74. Wild C.P., Yin F., Turner P.C., Chemin I., Chapot B., Mendy M., et al. Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int J Cancer 2000, 86:1-7.
75. Yu M.C., Yuan J.M., Govindarajan S., Ross R.K. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000, 14:703-709.
76. Yu M.W., Chang H.C., Liaw Y.F., Lin S.M., Lee S.D., Liu C.J., et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000, 92:1159-1164.
77. Yucesoy B., Johnson V.J., Fluharty K., Kashon M.L., Slaven J.E., Wilson N.W., et al. Influence of cytokine gene variations on immunization to childhood vaccines. Vaccine 2009, 27:6991-6997.
78. Zhang H., Zhai Y., Hu Z., Wu C., Qian J., Jia W., et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010, 42:755-758.
79. Zheng M.H., Qiu L.X., Xin Y.N., Pan H.F., Shi K.Q., Chen Y.P. Tumor necrosis factor-alpha-308A allele may have a protective effect for chronic hepatitis B virus infection in Mongoloid populations. Int J Infect Dis 2010, 14:e580-e585.
80. Zuckerman J.N. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006, 78:169-177.